Drugs / SC0191
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06055348 | Oct 2023 → Aug 2025 | malignant ovarian serous tumor | Biocity Biopharmaceutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06363552 | May 2024 → Apr 2025 | colorectal cancer | Tianshu Liu | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC0191 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06055348 ↗ |
| Modality | Small molecule | — CHEMBL6068560 ↗ |
| Route | Oral | “SC0191 PO will be taken” NCT06055348 ↗ |